罗浮山宫炎平品牌怎么样 申请店铺

我要投票 罗浮山宫炎平在女性洗液行业中的票数:615 更新时间:2026-01-02
罗浮山宫炎平是哪个国家的品牌?「罗浮山宫炎平」是 广东罗浮山国药股份有限公司 旗下著名品牌。该品牌发源于广东省惠州市,由创始人王 * 良在1970年期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力罗浮山宫炎平品牌出海!将品牌入驻外推网,定制罗浮山宫炎平品牌推广信息,可以显著提高罗浮山宫炎平产品曝光,简直是跨境电商爆单神器!目前仅需1000元/年哦~

罗浮山宫炎平怎么样

广东罗浮山国药股份有限公司,座落在广东罗浮山脚下,其前身——罗浮山药业始建于1970年,至今已有四十年发展史。公司投资上亿元按GMP标准建成了产、销一体的“罗浮山药业城”,占地面积10万多平方米、建筑面积8万平方米,至今已成为拥有员工近4000人、年纳税额超四千万元的大中型企业,是目前惠州市规模较大的制药企业,也是广东省内产能较大、剂型较齐全的中成药制剂企业之一。公司位于穗深经济走廊中心,旺盛的珠三角地域,毗邻港澳,交通四通八达,环境优雅。

罗浮山国药追求“以质量为本,科技创新”的经营理念,以继承和发扬具有1600多年历史的罗浮山中医药文化为已任,以造福百姓健康为宗旨,从事中西药品的开发、生产、销售以及中药材种植、生产加工和经营。四十年来,罗浮山国药不断挖掘和继承古代医药精华,利用当地丰富的中草药资源,系列颇具特色的品种、中药保护品种畅销国内外。公司现拥有的十一个剂型12条生产线全部通过国家GMP认证。年生产能力达片剂130亿片、颗粒剂3000吨、硬胶囊3亿粒、小容量注射剂2亿支、茶剂800万袋、搽剂8000万瓶、滴丸3亿粒、软胶囊2亿粒、栓剂5000万粒;提取车间年加工中药材可达2万吨,是广东省规模较大的中药提取车间之一。企业销售额每年以20-30%的幅度稳步增长。

朝气蓬勃的罗浮山国药已逐步发展壮大成为一个集科研、生产、销售和药材种植于一体的现代化高科技制药企业。随着企业不断发展壮大,坚信罗浮山国药将走在国内同行业的前列,屹立于中华药业之林。


Guangdong Luofushan Guoyao Co., Ltd. is located at the foot of Guangdong Luofushan. Its predecessor, Luofushan pharmaceutical industry, was founded in 1970 and has a history of 40 years. The company has invested more than 100 million yuan to build a "Luofushan pharmaceutical city" integrating production and marketing according to GMP standards, covering an area of more than 100000 square meters and a building area of 80000 square meters. So far, it has become a large and medium-sized enterprise with nearly 4000 employees and an annual tax payment of more than 40 million yuan. It is a large-scale pharmaceutical enterprise in Huizhou at present, and a Chinese patent medicine preparation with large production capacity and complete dosage forms in Guangdong Province One of the enterprises. The company is located in the center of suishen economic corridor, the exuberant Pearl River Delta region, adjacent to Hong Kong and Macao, with convenient transportation and elegant environment. Luofushan national medicine pursues the business philosophy of "quality-oriented, scientific and technological innovation", inherits and develops the culture of Luofushan Chinese medicine with a history of more than 1600 years, and aims to benefit the people's health. It is engaged in the development, production and sales of Chinese and Western medicine as well as the cultivation, production, processing and management of Chinese medicine. Over the past forty years, Luo Fu Shan has continuously excavated and inherited the essence of ancient medicine, and made use of the rich resources of Chinese herbal medicine, and a series of distinctive varieties and traditional Chinese medicine protection varieties have been sold well both at home and abroad. The company now has 11 dosage forms and 12 production lines, all of which have passed the national GMP certification. With an annual production capacity of 13 billion tablets, 3000 tons of granules, 300 million hard capsules, 200 million small volume injections, 8 million tea bags, 80 million bottles of liniments, 300 million drop pills, 200 million soft capsules and 50 million suppositories, the extraction workshop can process 20000 tons of traditional Chinese medicine annually, which is one of the large-scale TCM extraction workshops in Guangdong Province. The sales volume of the enterprise increases steadily by 20-30% every year. The vigorous Luofushan national medicine has gradually developed into a modern high-tech pharmaceutical enterprise integrating scientific research, production, sales and medicine planting. With the continuous development and growth of the enterprise, we firmly believe that Luofushan Guoyao will be in the forefront of the same industry in China and stand in the forest of Chinese pharmaceutical industry.

本文链接: https://brand.waitui.com/08d919ee4.html 联系电话:请联系客服添加 联系邮箱:请联系客服添加

外推网广告位招租,每天只要9块9

7×24h 快讯

印度政府批准电子元件制造计划下的投资金额为4186.3亿卢比

印度政府批准电子元件制造计划下的投资金额为4186.3亿卢比。(财联社)

2小时前

分析师:三星SDI或将持续亏损直至2026年底

NH Investment & Securities以Ju Min-woo为首的分析师表示,三星SDI在2025年第四财季因美国电动汽车需求疲软而录得大于预期的亏损后,可能会持续亏损直至2026年底。这些分析师表示,由于在欧洲的电动汽车电池市场份额不断下滑,这家韩国电池制造商可能比竞争对手受到更大冲击。NH Investment & Securities预计,该公司第四财季将录得3,387亿韩元的营业亏损,而市场平均预期为亏损2,690亿韩元,并预计其2025年年度亏损为1.765万亿韩元。NH Investment & Securities预测,该公司2026年的营业亏损可能收窄至9,670亿韩元。(新浪财经)

2小时前

葡萄牙12月特斯拉新车注册量同比下降12.7%,2025年累计下降22.3%

据葡萄牙汽车协会(ACAP),葡萄牙12月特斯拉新车注册量同比下降12.7%,2025年累计下降22.3%。(财联社)

2小时前

元旦假期首日,全社会跨区域人员流动量超2亿人次

2026年1月1日,全社会跨区域人员流动量20747.5万人次,环比下降0.1%,同比增长20.3%。(央视新闻)

2小时前

挪威2025年新车销量的96%为电动汽车

上周五的官方数据显示,去年在挪威注册的几乎所有新车都是纯电动汽车,其中特斯拉的销量更是一路飙升,使这个北欧国家在逐步淘汰汽油和柴油动力汽车方面巩固了全球领先地位。在税收优惠政策的推动下,2025年注册的所有新车中有95.9%是电动汽车,12月份这一数字接近98%。挪威道路联合会(OFV)的数据显示,这一年度数字高于2024年的88.9%。OFV称,挪威今年登记的新车数量达到创纪录的179549辆,比2024年增长了40%。(新浪财经)

2小时前

本页详细列出关于罗浮山宫炎平的品牌信息,含品牌所属公司介绍,罗浮山宫炎平所处行业的品牌地位及优势。
咨询